Background and aim: Peripheral arterial disease (PAD), an important manifestation of
Introduction
Peripheral arterial disease (PAD), an important manifestation of systematic atherosclerosis, is highly prevalent in hemodialysis (HD) patients (Lim et al., 2005; Jabbari et al., 2012) . Nevertheless, PAD is usually underdiagnosed and undertreated or even delayed treatment, since most patients were asymptomatic. We are well aware that adverse outcomes such as cardiovascular diseases (Liu et al., 2009; Kuwahara et al., 2014) and vascular access failure (Chen et al., 2009; Singh et al., 2015) are correlated to PAD. Therefore, early identification of asymptomatic PAD cases in HD patients is crucial for nephrologists.
An ankle-brachial index (ABI) of 0.9 or less is the currently accepted criterion for clinical diagnosis of PAD (Chen et al., 2010; Garimella et al., 2012; Tendera et al., 2011) . It is theoretically well known that a relaxing diagnostic threshold may result in a higher sensitivity.
In addition, evidence indicated that the adverse-prognosis risk of dialysis patients with ABI above 0.9 could be further classified by ABI levels (Ono et al., 2003) . With an idea of empirically validating, we retrospectively analyzed a cohort of HD patients to assess if using any lenient criterion of ABI could help predicting future risk of asymptomatic PAD in HD patients.
Methods
The medical records of a cohort of 275 outpatient HD patients were retrieved for eligibility identification and study data collection. The study observation period was designed as 2008/1/1~2013/9/30. The practice guideline was prepared following Ono et al [11] . Further detailed description on the cohort inclusion/exclusion criteria and on ABI surveillance implementation were included in Lim et al. (2016) .
This study was approved by the institutional review board of (Tungs' Taichung MetroHarbor Hospital (TTMHH, No: 103020) . The written informed consent was waived 6 because no invasive manipulations were involved in this study, the ABI surveillance and all study observations had been included in regular assessments in the HD unit of TTMHH since December 2006, and the data were analyzed anonymously.
The Cox regression were applied to assess the association between ABI level and the risk of PAD incidence whose baseline ABIs were all above 0.9 (ABI≤0.9 is the currently accepted criterion for PAD) (Chen et al., 2010; Garimella et al., 2012) . Survival time was the duration from the date of study follow-up beginning to the first date when a subsequent ABI value was below 0.9. Patients who maintained at normal ABI levels throughout the follow-up were censored by the follow-up end. Chi-square test and ANOVA were applied as appropriate to evaluate the statistical association at a significant level of 0.05.
Results
Of the 217 eligible cases, 72 (33.18%) prevalent cases manifested a baseline ABI below 0.9 in January 2008, 47 (21.66%) incident cases had some subsequent ABI measurements below 0.9 during the study observation period, and 98 (45.16%) non-PAD cases whose ABI measurements maintained above 0.9 throughout the study observation period. During the follow-up (mean±standard deviation: 5±1.3 years), the annual PAD incidence in the first four years were 11.72%, 20.02%, 28.18%, and 37.04%.
In the incident cohort (n=145), conventional risk factors of PAD including old age, diabetes mellitus (DM), coronary artery disease (CAD)/cerebrovascular disease (CeVD), high body mass index (BMI), high triglyceride to cholesterol ratio (rTG), low level ratio of high density lipoprotein cholesterol (rHDL), and high fasting blood sugar (FBS) were associated with higher PAD incidence (see Table 1 for the detailed results). After adjusting all potential risk factors of PAD, an interesting result was found. Among HD patients with baseline ABI above 0.9, those with baseline ABI below 1 (≤ 1) manifested a significantly higher risk of For an empirical exploration on biological plausibility, we evaluated the patterns of common medical conditions related to PAD patients among three groups of baseline ABI level (see Table 2 ). There was no significant difference in clinical correlates such as DM, CeVD, FBS, TG, rTG, and rHDL between patients with middle-level baseline ABI (>0.9 and ≤1) and with low-level baseline ABI (≤0.9). However, significant difference between patients with middle-level baseline ABI and with high-level baseline ABI (>1) was found in DM, CeVD, BMI, FBS, TG, and rTG. This indicated that even the conventional diagnosis criterion for PAD is ABI level of below 0.9, another accommodative cut-off point for early detecting of asymptomatic PAD should be considered for HD patients with ABI level above 0.9.
Discussion
In this retrospective cohort, a significantly higher incidence of PAD was observed in HD patients with baseline ABI between 0.9 and 1. Interestingly, for these patients the pattern of risk factors observed was similar to those HD patients having ABI <0.9. Clearly, we are aware that the value of 0.9 is somewhat arbitrary, as the ABI is a continuous variable that indicates the severity of the atherosclerotic process. A low normal value could be sometimes the sign of an early or moderate atherosclerotic process of vessels of lower limbs. Therefore, to allow earlier detection of asymptomatic PAD, a higher ABI cut-off point was suggested for maintenance HD patients. Evidence for such a view also comes from previous studies. Ono et al. (2003) found that HD patients with ABI in the range of 0.9-1 manifested significantly poor prognosis compared to patients with ABI in the range from 1 to 1.3. The abnormally stiff ankle arteries of HD patients due to medial arterial calcification might lead to more false negatives during ABI screening (Adragao et al., 2012). 8 Another interesting finding in this study was that patients with ABI in the range 0.9-1 manifested different prevalent rates of concomitant CAD and of CeVD at baseline. This group of patients appears to have similar CAD outcomes to patients with ABI in the range 1-1.3. In contrast, their CVD outcomes appear comparable to those with ABI in the range < 0.9. It is well-known that atherosclerosis is a systemic process with variable expression in different vascular beds. Reasons for differential anatomic expression of atherosclerosis may involve the interplay between inflammation, shear stresses, flow characteristics, and other local factors. Accumulating recent evidence found that PAD patients had higher prevalence of concomitant cerebrovascular disease than coronary disease (Steg et al., 2007; CAPRIE Steering Committee, 1996; Abbott et al., 2001; Ovbiagele, 2009) . Using data from the National Health and Nutrition Examination Survey, Ovbiagele (2009) found that only ABI < 0.9 and 0.9-0.99 were significantly associated with presence of CVD as compared with the reference group (ABI in 1.10-1.29) after adjusted for related risk factors. In addition, patients with PAD have been shown to have an elevated prevalence of carotid stenosis (Kurvers et al., 2003; Long et al., 1999; Cheng et al., 1999) . The risk of stroke rises with higher degree of symptomatic carotid stenosis (Jeng et al., 1994; De Weerd et al., 2010; Katsumata et al., 2007) . In a study in Chinese patients, Cheng et al. (1999) found that moderate to severe carotid stenosis in 24.5% of patients with PAD but only 11% in patients suffering from CAD, suggesting a stronger link between CVD and PAD.
Since the arteries of the great toe are rarely involved in the calcification process, the toe-brachial index (TBI) is considered as an alternative for detection of PAD complicated with incompressible vessels. Recently, Matsuzawa and colleagues (2015) reported a superior sensitivity on TBI than on ABI (1 vs. 0.58) and concluded that "screening for PAD using the ABI and TBI increased diagnostic efficiency in patients on HD". In clinical practice, TBI measurements are more cumbersome, since features common in dialysis patients such as 9 deformed toenails, thickened toenails, repeated microtrauma or ulcer on toe, scabbed toes, and tinea pedis may render the measurements more time-consuming and technically difficult.
Besides at present, there is lack of normative value from a large dialysis population that can define PAD in HD patients and hence there has been no consensus over the threshold of TBI.
Admittedly, a higher threshold theoretically resulted in higher sensitivity and also higher false positively rate. Several studies suggest that the ABI trend estimated from multiple ABI measurement is another predictor for outcomes relevant to PAD (Kuwahara et al., 2014; Chen et al., 2012; Feringa et al., 2007 ). An intensively multiple ABI surveillance following an initial one-shot examination with a higher threshold (ABI ≤ 1) could be a way to detection false positive cases in the initial examination, while the practical implementations needs further investigation. The unavailable data regarding the ascertainment of PAD by angiographic evaluation are a limitation of this retrospective cohort study. This impedes us to perform an ROC analysis, while efforts on such aspects will be pursued in future study.
Hopefully, our findings may shed some new light on the issue.
Conclusion
Our findings imply that intensive surveillance, and advanced diagnostic workup should be considered for hemodialysis patients with ABI values within the lower normal range (0.9-1). Clearly, the sensitivity of currently used threshold needs to be re-evaluated in this vulnerable group of patients with advanced atherosclerosis.
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